PMCB — Pharmacyte Biotech Cashflow Statement
0.000.00%
- $6.12m
- -$10.64m
- 45
- 83
- 24
- 50
Annual cashflow statement for Pharmacyte Biotech, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.83 | -3.55 | -4.24 | -4.32 | 0.334 |
| Non-Cash Items | 1.22 | 0.366 | 0.113 | 0.819 | -2.78 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.267 | -0.146 | 0.009 | -0.297 | 0.299 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -2.34 | -3.33 | -4.12 | -3.79 | -2.15 |
| Other Investing Cash Flow Items | 0 | 0 | 0 | 0 | -5 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0 | 0 | 0 | 0 | -5 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.73 | 4.64 | 87.3 | -13.6 | -10.7 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.38 | 1.31 | 83.2 | -17.4 | -17.9 |